Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 9;15(1):416.
doi: 10.1007/s12672-024-01300-w.

Adverse drug reactions and drug-related problems with supportive care medications among the oncological population

Batoul Barari Tajani  1 , E Maheswari  2 , Vinayak V Maka  3 , Anjana S Nair  4
Affiliations

Adverse drug reactions and drug-related problems with supportive care medications among the oncological population

Batoul Barari Tajani et al. Discov Oncol. .

Abstract

Aim: The current study emphasizes the impact of adverse drug reactions (ADRs) and Drug-Related Problems (DRPs) caused by supportive care medications administered with chemotherapy.

Method: This is a longitudinal observational study carried out at the Ramaiah Medical College Hospital in Bengaluru, Karnataka, India, at the Department of Oncology. The data was recorded using a specifically created data collecting form. Based on the PCNE (Pharmaceutical Care Network Europe), DRPs are identified. The WHO probability scale, Modified Hartwig and Siegel for ADR severity assessment, Naranjo's algorithm for causality assessment, Rawlins and Thompson for predictability assessment, and Modified Shumock and Thornton for preventability assessment were all utilized. The OncPal guideline was considered in terms of the precision of supportive care medications regarding the reduction of ADRs in cancer patients.

Result: We enrolled 302 patients,166 (55%) female and 136 (45%) male (SD 14.378) (mean 49.97), patients with one comorbidity 59(19.6%) and multimorbidity (two or more) 45(14.9%), the DRPs identified were found to be 153 (50.6%); only P2 (safeties of drug therapy PCNE) were considered in this study. ADRs which are identified 175(57.9%) contributed/caused by the supportive care medications. WHO probability scale: 97 (32.1%) possible and 60 (19.9%) unlikely; Naranjo's algorithm: 97 (32.1%) unlikely and 69 (22.8%) possible; ADR severity assessment scale (Modified Hartwig and Siegel): 95 (31.5%) mild and 63 (20.9%) moderates; Rawlins and Thompson for determining predictability of an ADR: 33 (10.9%) predictable and 137 (45.5%) non-predictable; and Modified Shumock and Thornton for determining preventability of an ADR: 81 (26.8%) probably preventable and 90 (29.8%) non-preventable. The statistical comparison through preforming t-test and measuring Chi-Square between group with ADRs and without ADRs shows in some variables, significantly (Alcohol consumption status, P = .019) and Easter Cooperative Oncology Group (ECOG) performance status P < 0.001.

Conclusion: Comprehensive assessment of supportive medications in cancer patients would enhance the patient management and therapeutic outcome. The potential adverse drug reactions (ADRs) caused by supportive care medications can contribute to longer hospital stays and interact with the systemic anti-cancer treatment. The health care professionals should be informed to monitor the patients clinically administered with supportive medications.

Keywords: Adverse drug reaction; Drug-related problem; OncPal guideline; PCNE classification; Supportive care medication.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Causality Assessment: a WHO-UMC probability scale b NARANJO’S algorithm c ADR severity assessment scale Modified Hartwig and Siegel d Predictability of an ADR Rawlins and Thompson e Preventability of an ADR Modified Shumock and Thornton
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Ahmed KO, Muddather HF, Yousef BA. Pharmaceutical Care Network Europe (PCNE) drug-related problems classification version 9.1: first implementation in Sudan. J Pharm Res Int. 2021. 10.9734/jpri/2021/v33i59a34321.10.9734/jpri/2021/v33i59a34321 - DOI
    1. Nabil S, El-Shitany NA, Shawki MA, et al. A pharmaceutical care plan to minimize the incidence of potential drug-related problems in cancer patients. Egypt J Hosp Med. 2022;89:4874–80. 10.21608/EJHM.2022.260758.10.21608/EJHM.2022.260758 - DOI
    1. Garin N, Sole N, Lucas B, et al. Drug related problems in clinical practice: a cross-sectional study on their prevalence, risk factors and associated pharmaceutical interventions. Sci Rep. 2021;11:1–11. 10.1038/s41598-020-80560-2. 10.1038/s41598-020-80560-2 - DOI - PMC - PubMed
    1. Yismaw MB, Adam H, Engidawork E. Identification and resolution of drug-related problems among childhood cancer patients in Ethiopia. J Oncol. 2020. 10.1155/2020/6785835. 10.1155/2020/6785835 - DOI - PMC - PubMed
    1. de Freitas GRM, Tramontina MY, Balbinotto G, et al. Economic impact of emergency visits due to drug-related morbidity on a Brazilian Hospital. Value Heal Reg Issues. 2017;14:1–8. 10.1016/j.vhri.2017.03.003.10.1016/j.vhri.2017.03.003 - DOI - PubMed

LinkOut - more resources